722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
Shibani Nicum, Jane Holmes, Naomi McGregor, R. Dunn, Linda Collins, S.B. Kaye, Iain A. McNeish, Rosalind Glasspool, Marcia Hall, René L. Roux, Agnieszka Michael, Susana Banerjee, Rebecca Kristeleit, G. Jayson, A. Clamp, Anita Mansouri
Topics & Concepts
OlaparibMedicinePaclitaxelOncologyOvarian cancerInternal medicineGynecologyCancerChemistryBiochemistryPolymerasePoly ADP ribose polymeraseGenePARP inhibition in cancer therapyOvarian cancer diagnosis and treatment